- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07747740
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (GEMDOC-MMC)
A Prospective, Randomized, Open-Label, Phase II Trial Comparing Sequential Intravesical Gemcitabine Plus Docetaxel With Sequential Intravesical Gemcitabine Plus Mitomycin C in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
연구 개요
상세 설명
High-grade BCG-unresponsive non-muscle-invasive bladder cancer remains a major therapeutic challenge. Radical cystectomy is considered the standard treatment; however, many patients are unwilling or medically unfit to undergo surgery. Sequential intravesical chemotherapy has emerged as a bladder-preserving treatment strategy with encouraging oncological outcomes.
This prospective, randomized, open-label, single-center phase II trial is designed to compare the efficacy and safety of two sequential intravesical chemotherapy regimens following complete TURBT.
Eligible patients with histologically confirmed BCG-unresponsive high-grade NMIBC will be randomized in a 1:1 ratio to receive either sequential intravesical gemcitabine followed by docetaxel or sequential intravesical gemcitabine followed by mitomycin C.
Both treatment regimens consist of a six-week induction course followed by monthly maintenance instillations for twelve months according to the study protocol. Clinical follow-up includes cystoscopy, urine cytology, pelvic ultrasonography, adverse event assessment according to CTCAE criteria, and quality-of-life evaluation using the EORTC QLQ-C30 and EORTC QLQ-NMIBC24 questionnaires.
The primary endpoint is 12-month event-free survival. Secondary endpoints include cystectomy-free survival, progression-free survival, safety, tolerability, and comparative efficacy of both treatment strategies.
A total of 228 participants will be enrolled. Statistical analyses will be performed according to the intention-to-treat principle using Kaplan-Meier survival analysis, log-rank testing, and Cox proportional hazards regression.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Nshan Sedrakyan, MD
- 전화번호: +79165663100
- 이메일: nick977773@gmail.com
연구 장소
-
-
Moscow
-
Moscow, Moscow, 러시아 제국, 115522
- 모병
- N.N. Blokhin National Medical Research Center of Oncology
-
연락하다:
- Nshan Sedrakyan, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed BCG-unresponsive non-muscle-invasive urothelial bladder cancer (NMIBC).
- Complete transurethral resection of bladder tumor (TURBT) before study treatment.
- Intermediate- or high-risk NMIBC according to current clinical guidelines.
- Candidate for intravesical chemotherapy.
- ECOG performance status 0-2.
- Adequate hematologic, renal, and hepatic function.
- Written informed consent.
Exclusion Criteria:
- Muscle-invasive (≥T2), locally advanced, or metastatic urothelial carcinoma.
- Upper urinary tract urothelial carcinoma requiring treatment.
- Previous hypersensitivity to gemcitabine, docetaxel, mitomycin C, or formulation components.
- Active uncontrolled urinary tract infection.
- Pregnancy or breastfeeding.
- Concurrent participation in another interventional clinical trial.
- Any serious uncontrolled medical condition that, in the investigator's opinion, would interfere with study participation or interpretation of results.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Sequential Gemcitabine + Docetaxel
Participants receive sequential intravesical gemcitabine followed by docetaxel after complete TURBT.
Treatment consists of six weekly induction instillations followed by monthly maintenance instillations for 12 months.
|
Intravesical gemcitabine 1 g dissolved in 50 mL of 0.9% sodium chloride.
The solution is retained in the bladder for 90 minutes before drainage.
Intravesical docetaxel 37.5 mg dissolved in 50 mL of 0.9% sodium chloride.
The solution is retained in the bladder for 90 to 120 minutes following gemcitabine administration.
다른 이름들:
|
|
활성 비교기: Sequential Gemcitabine + Mitomycin C
Participants receive sequential intravesical gemcitabine followed by mitomycin C after complete TURBT.
Treatment consists of six weekly induction instillations followed by monthly maintenance instillations for 12 months.
|
Intravesical gemcitabine 1 g dissolved in 50 mL of 0.9% sodium chloride.
The solution is retained in the bladder for 90 minutes before drainage.
Intravesical mitomycin C 40 mg dissolved in 40 mL of 0.9% sodium chloride.
The solution is retained in the bladder for 90 minutes following gemcitabine administration.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
12-Month Event-Free Survival
기간: 12 months after randomization
|
Event-free survival is defined as the time from randomization to the first occurrence of histologically confirmed recurrence, disease progression to muscle-invasive bladder cancer, radical cystectomy, distant metastasis, or death from any cause.
|
12 months after randomization
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival
기간: Up to 12 months
|
Time from randomization to progression to muscle-invasive or metastatic urothelial carcinoma.
|
Up to 12 months
|
|
Cystectomy-Free Survival
기간: Up to 12 months
|
Time from randomization to radical cystectomy for bladder cancer.
|
Up to 12 months
|
|
Treatment-Related Adverse Events
기간: Throughout study treatment and follow-up
|
Incidence and severity of adverse events graded according to CTCAE.
|
Throughout study treatment and follow-up
|
|
Health-Related Quality of Life (EORTC QLQ-C30)
기간: Baseline through 12 months
|
Change from baseline in EORTC QLQ-C30 scores.
|
Baseline through 12 months
|
|
Health-Related Quality of Life (EORTC QLQ-NMIBC24)
기간: Baseline through 12 months
|
Change from baseline in EORTC QLQ-NMIBC24 scores.
|
Baseline through 12 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Vsevolod Matveev, MD, PhD, N.N. Blokhin National Medical Research Center of Oncology
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 남성 비뇨 생식기 질환
- 비뇨기과 질환
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 조직학적 유형에 따른 신생물
- 신생물, 선상 및 상피
- 비뇨기과 신생물
- 암종
- 방광 질환
- 방광 신생물
- 비근육 침습성 방광 신생물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 박습니다
- 사이클로 데카네
- Diterpenes
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 도세탁셀
- 젬시타빈
기타 연구 ID 번호
- NMIBC-GEMDOC-001
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .